Cellestia

Cellestia
Cellestia
Clinical stage biopharma company active in the field of precision oncology.

Cellestia is giving hope to cancer patients who have no other treatment or therapy options by developing innovative targeted therapies. Our drug discovery platform is built on a unique mode of action of targeting protein-protein interactions (PPI) with small molecules. Together with companion diagnostics, Cellestia provides a first-in-class solution for NOTCH-driven cancers. Our clinical candidate drug CB-103 is targeting orphan cancers such as cancer of the salivary gland (adenoid cystic carcinoma) and a subtype of childhood leukaemia. At the same time, we are continuing to expand our portfolio through (i) targeting large cancer indications with CB-103, such as breast cancer, and (ii) developing novel PPI inhibitors for additionnal oncology indications. Cellestia is a privately-owned clinical-stage biopharma company (phase I) led by an experienced team of scientists, drug developers and business professionals.

Basel, Switzerland
Pharmaceuticals, Biopharma, health tech, cellestia, Basel
2014
https://www.cellestia.com/

Articles about Cellestia:

💡 You’re a corporate or investor and looking for startups that are innovating in the same market as Cellestia? We’re happy to assist you with our Startup Sourcing service.